41
Participants
Start Date
May 25, 2022
Primary Completion Date
November 1, 2023
Study Completion Date
March 30, 2024
AV7909
AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
AV7909
AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)
NIH